In HF with iron deficiency, IV ferric derisomaltose was associated with lower rates of HF hospitalization or CV death.
Ann Intern Med
; 176(4): JC40, 2023 04.
Article
em En
| MEDLINE
| ID: mdl-37011388
SOURCE CITATION: Kalra PR, Cleland JG, Petrie MC, et al. Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial. Lancet. 2022;400:2199-209. 36347265.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Anemia Ferropriva
/
Deficiências de Ferro
/
Insuficiência Cardíaca
Tipo de estudo:
Clinical_trials
/
Observational_studies
/
Risk_factors_studies
Limite:
Humans
Idioma:
En
Ano de publicação:
2023
Tipo de documento:
Article